Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for potentially curative treatment of HBV infections.
Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in clinical development as the backbone of an oral, once-daily potential curative therapy for Hepatitis B Virus. To date, we have completed extensive pre-clinical work, as well as Phase 1 studies in both healthy volunteers and HBV-infected individuals. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
B2B
26 to 50
Series B
$125.4 M
Scaling Up
2018
Healthcare
Biotechnology
Pharmaceuticals
N/A
Increase Efficiency
Production
Yes
Active
N/A
N/A
Software
N/A
N/A
13
1
$96M
Company was founded 2018 and it took almost 3 years (Apr 2021) to raise first external round
Investors
Interested in researching Antios Therapeutics?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Antios Therapeutics
Potential Customers
Interested in what they do or partnership?
Learn more about how they work